There have been major advances in our understanding of the cellular and molecular biology
of the human malignancies that are collectively referred to as ovarian cancer. At a recent …

The greatest unmet needs in biomarker discovery are those discoveries that lead to the
development of clinical diagnostic tests. These clinical diagnostic tests can provide early …

The introduction of technologies such as mass spectrometry and protein and DNA arrays,
combined with our understanding of the human genome, has enabled simultaneous …

A variety of biomarkers have been developed to monitor growth of ovarian cancer and to
detect disease at an early interval. CA125 (MUC16) has provided a useful serum tumor …

Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological
cancers. Less than 30% of women with advanced stage disease survive long‐term. When …

High-throughput biological assays such as microarrays let us ask very detailed questions
about how diseases operate, and promise to let us personalize therapy. Data processing …

The replication of scientific findings using independent investigators, methods, data,
equipment, and protocols has long been, and will continue to be, the standard by which …

Pancreatic cancer is a deadly disease and the fourth most common cause of cancer death in
the United States. Since chemotherapy and radiotherapy have thus far largely failed to …

Concurrent with the explosion in the number of publications reporting biomarker discovery
by profiling technologies, such as proteomics and pattern recognition, has been the increase …

Worldwide, the estimated annual incidence of ovarian cancer is 204,000, with 125,000
deaths. In developed countries, ovarian cancer remains the most lethal of all gynecologic …